Modern flu vaccine shows positive trials, a combination shot mode

Modern He said his experimental on Monday MRNA-based flu vaccine The stronger immune judgment found in a trial available today, the path to the product and clearing the distinctive combination of the company and Covid Jab.

Modern in May an application was voluntarily withdrawn According to Covid-19 and the goal of the flu, he was looking for approval of his combination, in order to resend the efficiency of the three trial phase data. After discussing this decision with food and drug administration, this is the Secretary of Health and Human Services Robert F. Kennedy Jr. Skeptical outstanding.

Along with new data, this year, Stephen Hoge, Stephen Hoge, plans to re-send the request to accept the company’s research and development of the company.

If the regulators support the flu vaccine, the company then can move forward shooting, Hoge said. He has added that the modern expects the approvals of both shots next year.

The modern shares rose by almost 3% on Premarches Monday.

Hoge said the jab combination simplifies vaccination.

So far the company’s race appears to be the front runner Pfizer and Novavax To take a combination to the market. While modern projection of the revenue of its individual products, Hoge said that Covid, flu and sinclytial respiratory virus is each sincytial.

“We hope our products allow us to win our fee fair fair,” he said.

The three trial phases followed more than 40,000 adults aged 50 years old, randomly assigned to receive a single dose of the modern shot, called MRNA-1010 or a standard competitor vaccine. The modern shot was 26.6% more than another vaccine.

MRNA-1010 Jab showed strong efficiency for large tensions in the shot flu, including A / H1N1, A / H3N2 and B / VICTORIA lineages. Modern said the vaccine benefit was consistent in different age groups, people with various risk factors and flu vaccination.

In adults aged 65 and over, the shot was 27.4% more than standard flu vaccine.

The results of efficiency “to reduce flu burgo” in our efforts “,” said Rephane Bancel Moderna Celoo Stephane Bancelek. “The severity of this past is to emphasize the need for more effective vaccinations.”

Modern Modern data From disease control and prevention centers, hospitalizations related to seasonal flu and outpatient visits from 1524 to 2024 The virus season was 15 years. More than 600,000 Americans Due to the disease associated with the last year, according to CDC.

The MRNA-1010 vaccine security data consistent with the result with other phases of the previous three phases.

Modern shares fell by more than 30% Monday, largely affected by the Trump Administration to change vaccination policy and a string of movement that weakens immunization. Administration in May canceled Thanks to the final development of the development of his bird flu vaccine for humans.

When asked about the regulatory regulatory environment in the US, Hoge said Modern has a strong link to the FDA to meet its demands and how to satisfy it.

“I think, according to the flu, I think we have a pretty light path,” he said.